Macrophage cholesterol homeostasis and metabolic diseases: Critical role of cholesteryl ester mobilization

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 3, 2011, Pages 329-340

  Ghosh, Shobha ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

atherosclerosis; cholesterol homeostasis; cholesteryl ester hydrolase; HDL; inflammation; macrophage

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER G1; ACYL COENZYME A; AMINOACYLTRANSFERASE; APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL ESTER; CHOLESTEROL ESTERASE; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PURINERGIC P2Y RECEPTOR; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; DRUG DOSE COMPARISON; GENE OVEREXPRESSION; HEART INFARCTION; HOMEOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; MACROPHAGE; METABOLIC DISORDER; REVIEW;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL ESTERS; HOMEOSTASIS; HUMANS; INFLAMMATION; LIPID MOBILIZATION; LIPOPROTEINS, HDL; MACROPHAGES; METABOLIC DISEASES;

EID: 79953239845     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.16     Document Type: Review

References (86)

1. D'Agostino RB, Russell MW, Huse DM et al. Primary and subsequent coronary risk appraisal: New results from the Framingham study. Am. Heart J. 139(2 Pt 1), 272-281 (2000). (Pubitemid 30090804)
2. Greenland P, Knoll MD, Stamler J et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 290(7), 891-897 (2003). (Pubitemid 37430460)
3. Ni H, Coady S, Rosamond W et al. Trends from 1987 to 2004 in sudden death due to coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Am. Heart J. 157(1), 46-52 (2009).
4. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
5. Baigent C, Keech A, Kearney PM et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005).
6. LaRosa JC, Grundy SM, Waters DD et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14), 1425-1435 (2005). First clear demonstration of residual cardiovascular disease (CVD) risk. (Pubitemid 40471450)
7. Fruchart JC, Sacks F, Hermans MP et al. The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol. 102(10 Suppl.), 1K-34K (2008). Position paper detailing the Residual Risk Initiative (R3I).
8. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62(5), 707-714 (1977). (Pubitemid 8110784)
9. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124, S11-S20 (1996).
10. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: Focus on antioxidative activities. Curr. Opin. Lipidol. 21(4), 312-318 (2010).
11. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol. Ther. 111(3), 893-908 (2006). (Pubitemid 44164383)
12. Heinecke JW. The HDL proteome: A marker - and perhaps mediator - of coronary artery disease. J. Lipid Res. 50, S167-S171 (2009). Pioneering work demonstrating the complexity of the proteins associated with HDL particles and their physiological role.
13. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: At the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J. 31(2), 149-164 (2010).
14. Brundert M, Heeren J, Merkel M et al. Scavenger receptor CD36 mediates uptake of high density lipoproteins by tissues in mice and by cultured cells. J. Lipid Res. DOI: 10.1194/jlr.M011981 (2011) (Epub ahead of print).
15. Fabre AC, Malaval C, Ben Addi A et al. P2Y13 receptor is critical for reverse cholesterol transport. Hepatology 52, 1477-1483 (2010).
16. Webb NR, Cai L, Ziemba KS et al. The fate of HDL particles in vivo after SR-BI- mediated selective lipid uptake. J. Lipid Res. 43, 1890-1898 (2002). (Pubitemid 35315807)
17. Webb NR, De Beer MC, Asztalos BF et al. Remodeling of HDL remnants generated by scavenger receptor class B type I. J. Lipid Res. 45, 1666-1673 (2004). (Pubitemid 39296206)
18. Kozyraki R, Fyfe J, Kristiansen M et al. The intrinsic factor-vitamin B12 receptor, cubilin, is a high affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat. Med. 5, 656-661 (1999). (Pubitemid 29289429)
19. Lee JY, Lanningham-Foster L, Boudyguina EY et al. Pre-b high density lipoprotein has two metabolic fates in human apolipoprotein A-I transgenic mice. J. Lipid Res. 45, 716-728 (2004). (Pubitemid 38405678)
20. Ghosh S, Zhao B, Bie J, Song J. Macrophage cholesteryl ester mobilization and atherosclerosis. Vascul. Pharmacol. 52(1-2), 1-10 (2010). Detailed review of intracellular CE hydrolysis and CEH characterization.
21. Jian B, de la Llera-Moya M, Royer L et al. Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid. J. Lipid Res. 38, 734-744 (1997). (Pubitemid 27194924)
22. Adorni MP, Zimetti F, Billheimer JT et al. The roles of different pathways in the release of cholesterol from macrophages. J. Lipid Res. 48(11), 2453-2462 (2007). Identification and quantification of cholesterol efflux by various pathways. (Pubitemid 350058756)
23. Zhao B, Song J, St Clair RW, Ghosh S. Stable over-expression of human macrophage cholesteryl ester hydrolase (ceh) results in enhanced free cholesterol efflux from human thp1-macrophages. Am. J. Physiol. Cell Physiol. 292(1), C405-C412 (2007). Development of a human macrophage cell system suitable for measuring efflux potential. (Pubitemid 46115148)
24. Zhou H, Tan KC, Shiu SW, Wong Y. Cellular cholesterol efflux to serum is impaired in diabetic nephropathy. Diabetes Metab. Res. Rev. 24(8), 617-623 (2008).
25. Zhou H, Shiu SW, Wong Y, Tan KC. Impaired serum capacity to induce cholesterol efflux is associated with endothelial dysfunction in Type 2 diabetes mellitus. Diab. Vasc. Dis. Res. 6(4), 238-243 (2009).
26. Ripollés Piquer B, Nazih H, Bourreille A et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: Consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism 55(7), 980-988 (2006). (Pubitemid 43922372)
27. Kruth HS. Sequestration of aggregated low-density lipoproteins by macrophages. Curr. Opin. Lipidol. 13(5), 483-488 (2002). (Pubitemid 35231927)
28. Kruth HS, Jones NL, Huang W et al. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem. 1280(3), 2352-2360 (2005).
29. Kruth HS, Huang W, Ishii I, Zhang WY. Macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem. 277(37), 34573-34580 (2002).
30. Choi SH, Harkewicz R, Lee JH et al. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ. Res. 104, 1355-1363 (2009).
31. Tabas I. Cholesterol and phospholipid metabolism in macrophages. Biochim. Biophys. Acta, 1529(1-3), 164-174 (2000).
32. Brown MS, Ho YK, Goldstein JL. The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and reesterification of cytoplasmic cholesteryl esters. J. Biol. Chem. 255(19), 9344-9352 (1980). (Pubitemid 11202897)
33. Rothblat GH, de la Llera-Moya M, Favari E, Yancey PG, Kellner-Weibel G. Cellular cholesterol flux studies: Methodological considerations. Atherosclerosis 163(1), 1-8 (2002). (Pubitemid 34615720)
34. Ishii I, Oka M, Katto N, Shirai K, Saito Y, Hirose S. b-VLDL-induced cholesterol ester deposition in macrophages may be regulated by neutral cholesterol esterase activity. Arterioscler. Thromb. 12, 1139-1145 (1992).
35. Mathur SN, Field FJ, Megan MB, and Armstrong HL. A defect in mobilization of cholesteryl esters in rabbit macrophages. Biochim. Biophys. Acta 834, 48-57 (1985). (Pubitemid 15097621)
36. Yancey PG and St. Clair RW. Mechanism of the defect in cholesteryl ester clearance from macrophages of atherosclerosissusceptible White Carneau pigeons. J. Lipid Res. 35, 2114-2129 (1994).
37. Brunham LR, Singaraja RR, Duong M et al. Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29(4), 548-554 (2009).
38. Burgess B, Naus K, Chan J et al. Overexpression of human ABCG1 does not affect atherosclerosis in fat-fed ApoEdeficient mice. Arterioscler. Thromb. Vasc. Biol. 28(10), 1731-1737 (2008).
39. Yvan-Charvet L, Ranalletta M, Wang N et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J. Clin. Invest. 117(12), 3900-3908 (2007). (Pubitemid 350224099)
40. Singaraja RR, Fievet C, Castro G et al. Increased ABCA1 activity protects against atherosclerosis. J. Clin. Invest. 110, 35-42 (2002). (Pubitemid 34743463)
41. Joyce CW, Wagner EM, Basso F et al. ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis. J. Biol. Chem. 281(44), 33053-33065 (2006). (Pubitemid 46036688)
42. Ye D, Lammers B, Zhao Y et al. ATPbinding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: Important targets for the treatment of atherosclerosis. Curr. Drug. Targets PubMed PMID: 21039336 (2010) (Epub ahead of print).
43. Sliskovic DR, White AD. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol. Sci. 12, 194-199 (1991).
44. Matsuda K. ACAT inhibitors as antiatherosclerotic agents. Med. Res. Rev. 14, 271-305 (1994).
45. Matsuo M , Ito F, Konto A, Aketa M, Tomoi M, Shimomura K. Effect of FR145237, a novel ACAT inhibitor on atherogenesis in cholesterol fed and WHHl rabbits. Evidence for a direct effect on the arterial wall. Biochem. Biophys. Acta 1259, 254-260 (1995). (Pubitemid 26018516)
46. Nicolosi RJ, Wilson TA, Krause BR. The ACAT inhibitor, CI 1011 is effective in the prevention and regression of aortic fatty streak in hamsters. Atherosclerosis 137, 77-85 (1998). (Pubitemid 28175379)
47. Perrey S, Legendre C, Matsuura A et al. Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis. Atherosclerosis 155, 359-370 (2001). (Pubitemid 32209306)
48. Accad M, Smith S, Newland D et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase-1. J. Clin. Invest. 105, 711-719 (2000). (Pubitemid 30164109)
49. Yagu H, Kitamine T, Osuga J et al. Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. J. Biol. Chem. 275, 21324-21330 (2000). (Pubitemid 30481831)
50. Fazio S, Major AS, Swift LL et al. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J. Clin. Invest. 107, 163-171 (2001). (Pubitemid 32096832)
51. Bocan TM, Krause BR, Rosebury WS et al. The ACAT inhibitor avasimbe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesion of hypercholesterolemic rabbits. Arteioscler. Thromb. Vasc. Biol. 20, 70-79 (2000). (Pubitemid 30048348)
52. Glass CK, Witztum JL. Atherosclerosis: The road ahead. Cell 104, 503-516 (2001). (Pubitemid 32201946)
53. Warner GJ, Stoudt G, Bamberger M, Johnson WJ, Rothblat GH. Cell toxicity induced by inhibition of acyl coenzyme A:cholesterol acyltransferase and accumulation of unesterified cholesterol. J. Biol. Chem. 270, 5772-5778 (1995).
54. Ghosh S, St Clair RW, Rudel LL. Mobilization of cytoplasmic CE droplets by over-expression of human macrophage cholesteryl ester hydrolase. J. Lipid Res. 44, 1833-1840 (2003). (Pubitemid 37356655)
55. Ghosh S. Cholesteryl ester hydrolase in human monocyte/macrophage: Cloning, sequencing and expression of full-length cDNA. Physiol. Genomics 2, 1-8 (2000).
56. Zhao B, Fisher BJ, St Clair RW, Rude LL, Ghosh S. Redistribution of macrophage cholesteryl ester hydrolase from cytoplasm to lipid droplets upon lipid loading. J. Lipid Res. 46, 2114-2121 (2005). (Pubitemid 41377463)
57. Crow JA, Middleton BL, Borazjani A, Hatfield MJ, Potter PM, Ross MK. Inhibition of carboxylesterase 1 is associated with cholesteryl ester retention in human THP-1 monocyte/macrophages. Biochim. Biophys. Acta 1781(10), 643-654 (2008).
58. Zhao B, Song J, Chow WN, St Clair RW, Rudel LL, Ghosh S. Macrophage-specific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr mice. J. Clin. Invest. 117(10), 2983-2992 (2007). First demonstration of a reduction in atherosclerosis by a targeted increase in macrophage CEH. (Pubitemid 47529628)
59. Zhao B, Song J, Ghosh S. Hepatic overexpression of cholesteryl ester hydrolase enhances cholesterol elimination and in vivo reverse cholesterol transport. J. Lipid Res. 49(10), 2212-2217 (2008). Identification of the role of hepatic CE hydrolysis in cholesterol elimination from the body.
60. Fazio S, Linton MF. The inflamed plaque: Cytokine production and cellular cholesterol balance in the vessel wall. Am. J. Cardiol. 88, 12E-15E (2001). Establishes the link between cellular cholesterol homeostasis and inflammation. (Pubitemid 32721977)
61. Koseki M, Hirano K, Masuda D et al. Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-a secretion in Abca1-deficient macrophages. J. Lipid Res. 48, 299-306 (2007). (Pubitemid 46220596)
62. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Natl Acad. Sci. USA 90, 12040-12044 (1993). (Pubitemid 24008776)
63. Francone OL, Royer L, Boucher G et al. Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages. Arterioscler. Thromb. Vasc. Biol. 25, 1198-1205 (2005). (Pubitemid 40776609)
64. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler. Thromb. Vasc. Biol. 30(2), 139-143 (2010). Current understanding of the role of cholesterol efflux and modulation of immune responses and inflammation.
65. Patel S, Drew BG, Nakhla S et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with Type 2 diabetes. J. Am. Coll. Cardiol. 53, 962-971 (2009).
66. Bie J, Zhao B, Song J, Ghosh S. Improved insulin sensitivity in high fat- and high cholesterol-fed Ldlr-/- mice with macrophage-specific transgenic expression of cholesteryl ester hydrolase: Role of macrophage inflammation and infiltration into adipose tissue. J. Biol. Chem. 285(18), 13630-13637 (2010). Direct demonstration of improvement in insulin sensitivity by modulating macrophage cholesterol homeostasis.
67. Besedovsky HO, Del Rey A. Metabolic and endocrine actions of interleukin-1. Effects on insulin-resistant animals. Ann. NY Acad. Sci. 594, 214-221 (1990). (Pubitemid 20298219)
68. Vozarova B, Weyer C, Hanson K, Tataranni P, Bogardus C, Pratley R. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes. Res. 9, 414-417 (2001). (Pubitemid 33603868)
69. Hotamisligil G, Shargill N, Spiegelman B. Adipose expression of tumor necrosis factor-a: Direct role in obesity-linked insulin resistance. Science 259, 87-91 (1993). (Pubitemid 23036092)
70. Taishi P, Churchill L, De A, Obal F, Krueger JM. Cytokine mRNA induction by interleukin-1b or tumor necrosis factor alpha in vitro and in vivo. Brain Res. 1226, 89-98 (2008).
71. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: Prevention by rosiglitazone. Biochem. Biophys. Res. Commun. 311, 372-379 (2003). (Pubitemid 37340087)
72. Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1b-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 148, 241-251, (2007). (Pubitemid 46021456)
73. Alvarez B, Quinn LS, Busquets B, Quiles MT, Lopez-Soriano FJ, Argiles JM. Tumor necrosis factor-a exerts interleukin-6- dependent and -independent effects on cultured skeletal muscle cells. Biochim. Biophys. Acta 1542, 66-72 (2002).
74. Maedler K, Dharmadhikari G, Schumann DM, Størling J. Interleukin-1b targeted therapy for Type 2 diabetes. Expert Opin. Biol. Ther. 9, 1177-1188 (2009).
75. Honda H, Qureshi AR, Heimburger O et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am. J. Kidney Dis. 47, 139-148 (2006). (Pubitemid 41828276)
76. Soriano S, Gonzalez L, Martin-Malo A et al. C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3-5 patients. Clin. Nephrol. 67, 352-357 (2007). (Pubitemid 46894799)
77. Shah DS, Polkinhorne KR, Pellicano R, Kerr PG. Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients? Nephrology (Carlton) 13, 667-671 (2008).
78. Parekh RS, Plantinga LC, Kao WH et al. The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int. 74, 1335-1342 (2008).
79. Yamamoto S, Kon V. Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Curr. Opin. Nephrol. Hypertens. 18(3), 181-188 (2009). Excellent review of the role of cholesterol homeostasis in determining the increased risk for CVD in chronic kidney disease.
80. Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl. Res. 153(2), 77-85 (2009).
81. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 290(17), 2292-2300 (2003). First clinical study to demonstrate regression of existing plaque by enhancing cholesterol efflux. (Pubitemid 37430562)
82. Vakili L, Hama S, Kim JB et al. The effect of HDL mimetic peptide 4F on PON1. Adv. Exp. Med. Biol. 660, 167-172 (2010).
83. Smith JD. Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr. Opin. Investig. Drugs 11(9), 989-996 (2010). Review of the current status of ApoA1 mimetics.
84. Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: A potential new therapy for the prevention of atherosclerosis. Cardiol. Rev. 18(3), 141-147 (2010).
85. White CR, Datta G, Mochon P et al. Vasculoprotective effects of apolipoprotein mimetic peptides: An evolving paradigm in HDL therapy. Vasc. Dis. Prev. 6, 122-130 (2009).
86. Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat. Clin. Pract. Cardiovasc. Med. 3(10), 540-547 (2006). (Pubitemid 44445797)